DOCSLIB.ORG

Ipratropium Bromide/Levosalbutamol 1125 Ipratropium Bromide May Also Be Given by Inhalation As a Neb- 4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ipratropium Bromide/Levosalbutamol 1125 Ipratropium Bromide May Also Be Given by Inhalation As a Neb- 4 Ipratropium Bromide/Levosalbutamol 1125 Ipratropium bromide may also be given by inhalation as a neb- 4. Bonadonna P, et al. Cold-induced rhinitis in skiers—clinical as- Profile ulised solution. UK licensed product information recommends pects and treatment with ipratropium bromide nasal spray: a ran- Isoetarine is a sympathomimetic with mainly beta-adrenergic ac- the following doses: domized controlled trial. Am J Rhinol 2001; 15: 297–301. tivity. It has actions similar to those of salbutamol (p.1131) but is 5. Kim KT, et al. Pediatric Atrovent Nasal Spray Study Group. Use • under 6 years, for the treatment of acute asthma only: 125 to of 0.06% ipratropium bromide nasal spray in children aged 2 to less selective for beta2 adrenoceptors. Isoetarine has been used as 250 micrograms, given no more often than every 6 hours up 5 years with rhinorrhea due to a common cold or allergies. Ann a bronchodilator in the management of reversible airways ob- to a total daily dose of 1 mg Allergy Asthma Immunol 2005; 94: 73–9. struction. • 6 to 12 years, for the treatment of acute or chronic asthma: Preparations Isoetarine is given by inhalation, as a nebulised solution of the 250 micrograms, repeated if necessary up to a total daily dose hydrochloride in strengths up to 0.25%; a 1% solution can be BP 2008: Ipratropium Nebuliser Solution; Ipratropium Powder for Inhala- given by a hand nebuliser. of 1 mg tion; Ipratropium Pressurised Inhalation. • 12 years and over: adult doses, see above. Proprietary Preparations (details are given in Part 3) Preparations Arg.: Aerotrop; Atrovent; Iprabron; Austral.: Aeron; Apoven; Atrovent; USP 31: Isoetharine Inhalation Solution; Isoetharine Mesylate Inhalation Ipratropium bromide is used in the management of rhinorrhoea Ipratrin; Ipravent; Austria: Atrovent; Itrop; Belg.: Atronase; Atrovent; Aerosol. associated with rhinitis. A dose of 42 micrograms may be given Braz.: Alvent†; Ares; Atrovent; Bromovent; Iprabon; Ipraneo; Canad.: into both nostrils two or three times daily. In the UK this dose Apo-Ipravent; Atrovent; Novo-Ipramide; Chile: Atrovent; Neorinol†; Cz.: may be given to children from 12 years of age, but in the USA Atrovent; Itrop†; Denm.: Atrovent; Fin.: Atrovent; Fr.: Atrovent; Ger.: this dose is licensed in children from 6 years of age. Atrovent; Itrop; Gr.: Atrovent; Hong Kong: Atrovent; Cyclovent; Levosalbutamol (rINN) ⊗ Ipravent†; Hung.: Atrovent; India: Ipranase; Ipravent; Indon.: Atrovent; US licensing also permits higher doses for up to 4 days when Irl.: Atrovent; Rinatec; Israel: Aerovent; Apovent; Atrovent; Ital.: Atem; Levalbuterol; Lévosalbutamol; Levosalbutamolum. (R)-α1-[(tert- rhinorrhoea is associated with the common cold: Rinovagos; Jpn: Atrovent; Malaysia: Atrovent; Mex.: Atrovent; Neth.: Butylamino)methyl]-4-hydroxy-m-xylene-α,α′-diol. Atrovent; Ipraxa; Norw.: Atrovent; Respontin†; NZ: Apo-Ipravent; Atrov- • 5 to 11 years: 84 micrograms into each nostril three times ent; Ipra†; Philipp.: Atrovent; Pol.: Atrovent; Port.: Atrovent; Rus.: Atro- Левосальбутамол daily vent (Атровент); S.Afr.: Atrovent; Ipvent; Singapore: Atrovent; Spain: C H NO = 239.3. Atrovent; Swed.: Atrovent; Switz.: Atrovent; Rhinovent; Thai.: Atrovent; 13 21 3 • 12 years and over: adult doses, see above Turk.: Atrovent; UAE: Atropulm; UK: Atrovent; Respontin; Rinatec; USA: CAS — 34391-04-3. Higher doses are also permitted in the USA for up to 3 weeks Atrovent; Venez.: Alovent. when rhinorrhoea is associated with seasonal allergic rhinitis. Multi-ingredient: Arg.: Berodual; Combivent; Ipradual; Iprasalb; Salbutral Children 5 years of age and over may be given the same dose as AC; Salbutrop†; Austral.: Combivent; Austria: Berodual; Berodualin; H OH Combivent; Di-Promal; Belg.: Combivent; Duovent; Braz.: Combivent; H adults, see above. Duovent; Canad.: Combivent; Duovent; ratio-Ipra Sal UDV; Chile: Berod- N CH3 ual; Combivent; Salbutral AC; Cz.: Berodual; Combivent†; Denm.: Berod- Asthma. Ipratropium bromide is currently recommended as an ual; Combivent; Fin.: Atrodual; Atrovent Comp; Fr.: Bronchodual; Combiv- adjunct to beta2 agonists in the management of acute severe asth- ent; Ger.: Berodual; Gr.: Berodual; Berovent; Hong Kong: Berodual†; H3C CH3 ma, see p.1108. Antimuscarinic drugs, mainly ipratropium but Combivent; Hung.: Berodual; India: Duolin; Fenovent; Indon.: Berodual; HO also including oxitropium (p.1129), glycopyrronium and atro- Combivent; Irl.: Combivent; Duovent; Ipramol; Ital.: Breva; Duovent; Ipraf- en; Malaysia: Berodual; Combivent; Duovent; Ipramol; Mex.: Berodual; pine, have been reviewed in the treatment of both acute and Combivent; Neth.: Berodual; Combivent; NZ: Combivent; Duolin; 1 OH chronic asthma. A systematic review and meta-analysis of the Philipp.: Berodual; Combipul; Combivent; Duavent; Pol.: Berodual; Port.: effectiveness of antimuscarinics in the treatment of acute asthma Berodual; Combivent; Rus.: Berodual (Беродуал); S.Afr.: Atrovent Beta; in children and adults, found they produced significant reduc- Berodual; Combivent; Duolin; Duovent; Sabax Combineb; Sabax Nebrafen; Singapore: Berodual; Combivent; Duovent; Spain: Berodual†; Combiv- Levosalbutamol Hydrochloride (rINNM) ⊗ tions in hospital admissions. Combined treatment with an in- ent; Legis†; Swed.: Combivent; Switz.: Berodual; Dospir; Thai.: Berodual; haled beta2 agonist also produced a significant increase in respi- Combivent; Inhalex; Punol; Turk.: Combivent; UK: Combivent; Duovent; Hidrocloruro de levosalbutamol; Levalbuterol Hydrochloride ratory function. Ipramol; USA: Combivent; DuoNeb; Venez.: Berodual; Combivent; Duo- (USAN); Lévosalbutamol, Chlorhydrate de; Levosalbutamoli Hy- lin; Duovent; Ipralin; Respidual. Systematic reviews of antimuscarinic drugs have concluded that drochloridum. (R)-α1-[(tert-Butylamino)methyl]-4-hydroxy-m- there is currently insufficient evidence to justify their routine use xylene-α,α′-diol hydrochloride. 2 3 in adults or children with chronic asthma. Левосальбутамола Гидрохлорид 1. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treat- Isoetarine (BAN, rINN) ⊗ C13H21NO3,HCl = 275.8. ment of children and adults with acute asthma: a systematic re- Isoetariini; Isoetarin; Isoetarina; Isoétarine; Isoetarinum; Iso- CAS — 50293-90-8. view with meta-analysis. Thorax 2005; 60: 740–6. etharine (USAN); Win-3406. 1-(3,4-Dihydroxyphenyl)-2-isopro- 2. Westby M, et al. Anticholinergic agents for chronic asthma in Pharmacopoeias. In US. adults. Available in The Cochrane Database of Systematic Re- pylaminobutan-1-ol. USP 31 (Levalbuterol Hydrochloride). A 1% solution has a pH views; Issue 3. Chichester: John Wiley; 2004 (accessed Изоэтарин of 4.5 to 5.5. Store in airtight containers at 20° to 25°, excursions 18/02/08). C H NO = 239.3. permitted between 15° and 30°. Protect from light. 3. McDonald NJ, et al. Anticholinergic therapy for chronic asthma 13 21 3 in children over 2 years of age. Available in The Cochrane Data- CAS — 530-08-5. base of Systematic Reviews; Issue 1. Chichester: John Wiley; ATC — R03AC07; R03CC06. Levosalbutamol Sulfate (rINNM) ⊗ 2003 (accessed 18/02/08). ATC Vet — QR03AC07; QR03CC06. Levalbuterol Sulfate (USAN); Lévosalbutamol, Sulfate de; Levos- Chronic obstructive pulmonary disease. Inhaled antimus- albutamol Sulphate; Levosalbutamoli Sulfas; Sulfato de levosalb- carinics, such as ipratropium bromide, are currently recommend- utamol. (R)-α1-[(tert-Butylamino)methyl]-4-hydroxy-m-xylene- OH ed as bronchodilators in chronic obstructive pulmonary disease αα′-diol sulfate (2:1). (COPD) guidelines, see p.1112. A systematic review compared Левосальбутамола Сульфат regular treatment with ipratropium (given for at least 4 weeks) CH3 with treatment using regular short-acting beta agonists in stable (C13H21NO3)2,H2SO4 = 576.7. 2 CAS — 148563-16-0. COPD;1 it found small benefits on lung function outcomes and HN CH3 quality of life with ipratropium compared with a short-acting HO beta agonist; a reduction in the requirements for oral corticoster- Levosalbutamol Tartrate (rINNM) ⊗ 2 OH CH3 oids was also seen. Combination therapy with ipratropium and a Levalbuterol Tartrate (USAN); Lévosalbutamol, Tartrate de; Lev- short-acting beta2 agonist was associated with some clinically o s a lb ut a m o li Ta r t r a s ; Ta r t r a t o d e l e vo s a l bu t am o l . ( α1R)-α1- meaningful lung function outcomes compared with the beta2 Isoetarine Hydrochloride (BANM, rINNM) ⊗ {[(1,1-Dimethylethyl)amino]methyl}-4-hydroxy-1,3-benzened- agonist alone, but these were not reflected in subjective improve- imethanol (2R,3R)-2,3-dihydroxybutanedioate (2:1). ments or symptom scores. Etyprenaline Hydrochloride; Hidrocloruro de isoetarina; Isoé- tarine, Chlorhydrate d’; Isoetarini Hydrochloridum; Isoetharine Левосальбутамола Тартрат A systematic review comparing ipratropium with a long-acting 2 Hydrochloride; N-Isopropylethylnoradrenaline Hydrochloride. 2(C13H21NO3),C4H6O6 = 628.7. beta2 agonist in stable COPD, found that salmeterol had more effect than ipratropium on lung function, but no major differenc- Изоэтарина Гидрохлорид CAS — 661464-94-4. es were seen between symptom responses to ipratropium and sal- C13H21NO3,HCl = 275.8. Adverse Effects and Precautions meterol. Combination treatment with these two drugs was better CAS — 50-96-4; 2576-92-3. As for Salbutamol, p.1131. than salmeterol alone in terms of quality of life. ATC — R03AC07; R03CC06. Incidence of adverse effects. Some studies have reported 1. Appleton S, et al. Ipratropium bromide versus short acting beta- ATC Vet — QR03AC07; QR03CC06.
Load more

Recommended publications
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • 1. Generic Names Levosalbutamol 0.25G Ambroxol 7.5Mg
    1. Generic Names Levosalbutamol 0.25g Ambroxol 7.5mg Guaiphenesin 12.5 mg 2. Qualitative and Quantitative Composition Each ml contains Levosalbutamol 0.25g Ambroxol 7.5mg Guaiphenesin 12.5 mg 3. Dosage form and strength Oral drop solution containing Levosalbutamol 0.25g, Ambroxol 7.5mg, Guaiphenesin 12.5 mg. 4. Clinical particulars 4.1 Therapeutic indication Kofarest-PD drops is indicated for the treatment of productive cough associated with bronchospasm in conditions such as bronchitis and bronchial asthma as well as all conditions associated with tenacious mucus, wheezing and chest congestion. 4.2 Posology and method of administration The usual recommended dose of KOFAREST-PD Drops in children is: 1-2 years age: 0.8 ml thrice a day 2-3 years age: 1.2 ml thrice a day. 4.3 Contraindication Kofarest-PD drops are contraindicated in patients with hypersensitivity to any ingredient of the formulation. 4.4 Special warnings and precautions for use While treating cough as a symptom, it is important to make every effort to determine and treat appropriately the underlying cause, such as a specific infection. Caution should be observed while prescribing Kofarest-PD drops to children with hypertension, cardiovascular disease, uncontrolled juvenile diabetes mellitus, hyperthyroidism, and seizures or in patients who are unusually hypersensitive to sympathomimetic amines. 4.5 Drug interactions Hypokalaemia with high doses of ß2 -agonists may result in increased susceptibility to digitalis induced cardiac arrhythmias. Hypokalaemia may be enhanced by concomitant administration of aminophylline or other xanthine, corticosteroids or by diuretic therapy. Other sympathomimetic bronchodilators or epinephrine should not be used concomitantly with salbutamol, since their combined effect on the cardiovascular system may be deleterious to the patient.
    [Show full text]
  • Supplementary Materials 07/09/2017
    SMART Adolescent manuscript: Supplementary materials 07/09/2017 Supplementary materials Methods Definition and calculation of severe exacerbations The first three studies conducted 10-12, defined severe exacerbations as the need for oral corticosteroid (OCS) and/or hospitalisation/emergency room care due to asthma and/or a decrease in peak expiratory flow (PEF) of ≥30% on two consecutive days compared with the run-in period. In these studies, exacerbations were to be treated with a 10-day OCS course; an exacerbation lasting >10 days was considered a new exacerbation on the 11th day. Based on this experience, the later three studies 13-15 did not include falls in PEF in the exacerbation definition, nor this stipulated OCS treatment time, defining a severe exacerbation as the need for OCS for ≥3 days and/or hospitalisation/emergency room care due to asthma worsening. For the purpose of this analysis, we defined a severe exacerbation as the need for OCS (for ≥3 days 10-12) and/or hospitalisation/emergency room care due to asthma worsening; to align with this definition, data from 3 of the included studies 13-15 were reanalysed to exclude PEF fall from the exacerbation definition. 1 SMART Adolescent manuscript: Supplementary materials 07/09/2017 Literature review to identify any additional studies We conducted a review to identify any additional randomised controlled trials (RCTs) evaluating a combination of inhaled corticosteroids (ICS) and a rapid- acting bronchodilator in a single inhaler for both maintenance and as-needed relief of symptoms
    [Show full text]
  • Sympathoadrenergic Modulation of Hematopoiesis: a Review of Available Evidence and of Therapeutic Perspectives
    REVIEW published: 05 August 2015 doi: 10.3389/fncel.2015.00302 Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives Marco Cosentino*, Franca Marino and Georges J. M. Maestroni Center for Research in Medical Pharmacology, University of Insubria, Varese, Italy Innervation of the bone marrow (BM) has been described more than one century ago, however the first in vivo evidence that sympathoadrenergic fibers have a role in hematopoiesis dates back to less than 25 years ago. Evidence has since increased showing that adrenergic nerves in the BM release noradrenaline and possibly also dopamine, which act on adrenoceptors and dopaminergic receptors (DR) expressed on hematopoietic cells and affect cell survival, proliferation, migration and engraftment ability. Remarkably, dysregulation of adrenergic fibers to the BM is associated with hematopoietic disturbances and myeloproliferative disease. Several adrenergic and dopaminergic agents are already in clinical use for non-hematological indications and with a usually favorable risk-benefit profile, and are therefore potential candidates for Edited by: non-conventional modulation of hematopoiesis. Wanda Lattanzi, Università Cattolica del Sacro Cuore, Keywords: dopamine, noradrenaline, adrenaline, adrenoceptors, dopaminergic receptors, hematopoiesis, Italy neuroimmune phamacology, drug repurposing Reviewed by: Sujit Basu, Introduction Ohio State University, USA Tsvee Lapidot, Weizmann Institute of Science, Israel The term ‘‘niche’’, derived from the Latin word ‘‘mytilus’’ (mussel), has eventually come to designate a shallow recess in a wall, as for a statue or other decorative object, in view of the *Correspondence: similarity with the shape of a seashell, and broadly a place suitable or appropriate for a person or Marco Cosentino, Center for Research in Medical thing.
    [Show full text]
  • Ipratropium Bromide(BAN, USAN, Rinn)
    1124 Bronchodilators and Anti-asthma Drugs Ipratropium Bromide (BAN, USAN, rINN) intensify this problem by increasing the production of aqueous 2. Sin DD, Tu JV. Lack of association between ipratropium bro- humour.6 Studies13,14 suggest that patients with a history of an- mide and mortality in elderly patients with chronic obstructive Bromuro de ipratropio; Ipratropii bromidum; Ipratropii Bromi- gle-closure glaucoma might be at an increased risk of developing airway disease. Thorax 2000; 55: 194–7. dum Monohydricum; Ipratropio bromidas; Ipratropiowy bro- glaucoma when nebulised ipratropium and salbutamol are used 3. Ringbæk T, Viskum K. Is there any association between inhaled ipratropium and mortality in patients with COPD and asthma? mek; Ipratropium bromid monohydrát; Ipratropium, bromure d’; together. Respir Med 2003; 97: 264–72. Ipratropiumbromid; Ipratropium-bromid; Ipratropiumbromidi; 1. Hall SK. Acute angle-closure glaucoma as a complication of Ipratropyum Bromür; Sch-1000; Sch-1000-Br-monohydrate. combined β-agonist and ipratropium bromide therapy in the emergency department. Ann Emerg Med 1994; 23: 884–7. Interactions R r S r ± (1 ,3 ,5 ,8 )-8-Isopropyl-3-[( )-tropoyloxy]tropanium bromide 2. Weir REP, et al. Pupil blown by a puffer. Lancet 2004; 363: For interactions associated with antimuscarinics in monohydrate. 1853. general, see Atropine, p.1220. However, these interac- Ипратропия Бромид 3. Kizer KM, et al. Blurred vision from ipratropium bromide inha- lation. Am J Health-Syst Pharm 2000; 57: 996–7. tions are not usually seen with antimuscarinics, such as C H BrNO ,H O = 430.4. 20 30 3 2 4. Bond DW, et al. Mydriasis due to self-administered inhaled ipratropium, given by inhalation.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • (19) 11 Patent Number: 6165500
    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
    [Show full text]
  • PRODUCT CATALOGUE 2021 Available on Product Known Teva Tech US EU Japan Korea Therapeutic Api IP File*** DMF DMF DMF DMF Area**
    S NH2 N N O O O HN CH OH 3 N O SO3H PRODUCT CATALOGUE 2021 Available on www.teva-api.com Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** A ABALOPARATIDE Osteoporosis ABEMACICLIB Oncology ABIRATERONE ACETATE Oncology ACALABRUTINIB Oncology AFATINIB Oncology ALCLOMETASONE DIPROPIONATE Dermatology ALLOPURINOL Rheumatology CEP AMCINONIDE Dermatology AMITRIPTYLINE HCl Neurology - Psychiatry CEP ANASTROZOLE Oncology CEP ANIDULAFUNGIN Infectious disease APALUTAMIDE* Oncology Coagulation APIXABAN inhibitors APREMILAST* Psoriasis ARIPIPRAZOLE* Neurology-Psychiatry CEP ATOMOXETINE HCl Neurology-Psychiatry ATORVASTATIN CALCIUM Lipid lowering CEP Preterm labor ATOSIBAN ACETATE prevention ATRACURIUM BESYLATE Muscle relaxant CEP AZACITIDINE Oncology AZITHROMYCIN DIHYDRATE Infectious disease CEP AZITHROMYCIN MONOHYDRATE Infectious disease CEP AZTREONAM* Infectious disease B BALOXAVIR Antiviral 2 Product Known Teva Tech US EU Japan Korea therapeutic api IP file*** DMF DMF DMF DMF area** BARICITINIB Rheumatology BECLOMETHASONE DIPROPIONATE Respiratory CEP BETAMETHASONE ACETATE Inflammation BETAMETHASONE BASE Dermatology CEP BETAMETHASONE DIPROPIONATE Dermatology CEP BETAMETHASONE VALERATE Dermatology CEP BICALUTAMIDE Oncology CEP BIVALIRUDIN Hematology BLEOMYCIN SULFATE Oncology BORTEZOMIB Oncology BREXANOLONE Neurology-Psychiatry BREXPIPRAZOLE Neurology-Psychiatry BROMOCRIPTINE MESYLATE Cardiovascular CEP BUDESONIDE Respiratory CEP BUPRENORPHINE BASE Neurology-Psychiatry CEP BUPRENORPHINE HCl Neurology-Psychiatry
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • JMSCR Vol||07||Issue||08||Page 49-58||August 2019
    JMSCR Vol||07||Issue||08||Page 49-58||August 2019 http://jmscr.igmpublication.org/home/ ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i8.08 An Observational Study of Drug Utilization Pattern and Pharmacovigilance of Infective Wheeze Associated Disorders in Children Authors Arthi S1*, Vanithasamuel2, Ramesh S3, Nirmala P4 1Post graduate, Department of Pharmacology, 2Professor, Department of Pharmacology 3Professor and Head, Department of Pediatrics, 4Professor and Head, Department of Pharmacology Rajah Muthiah Medical College, Chidambaram 608002 *Corresponding Author Arthi S Post graduate, Department of Pharmacology, Rajah Muthiah Medical College, Chidambaram 608002, India Abstract Background: Wheeze associated lower respiratory tract infections occurring world-wide are prevalent most commonly in childhood. Observational drug utilization studies help to evaluate, interpret and improve drug use as well as monitor the efficacy and safety of drugs prescribed. There was no previous documentation on drug utilization pattern of wheeze associated lower respiratory tract infections in the pediatric age group. Therefore, this study analyses the prescription pattern and adverse effects observed in such disorders in children attending the Pediatric outpatient department in a tertiary care hospital in Chidambaram. Materials and Methods: 100 prescriptions from the Pediatric department of Raja muthiah Medical College and hospital were analyzed. Data collected from parents or care givers relating to wheeze associated respiratory disorders was evaluated for prescription pattern, drug efficacy, adverse effect and compliance observed in polytherapy. Results: Majority of the children irrespective of severity received inhalation of β2 agonist levosalbutamol as a bronchodilator and sodium chloride (Nacl) nebulization compared to oral formulations in children.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]